What changed
$NTRA — WATCHLIST 📊
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
🎯 Q2 2026 | Rev $1B | EPS $-0.60 vs $-0.55 🔴
💡 Consensus expects continued quarterly losses and a slow path to breakeven, with decelerating revenue growth. The variant view sees faster-than-expected revenue acceleration from Signatera adoption and NIPT share gains, leading to positive earnings surprises in 4-6 quarters, but this is not yet reflected in the recent earnings miss and rich...
📉 Reward/Risk: 2.0:1
🏢 Business Quality: 8/10 - Dominant NIPT franchise with >40% market share, proprietary technology, high switching costs, and expanding oncology liquid biopsy platform (Signatera) with large TAM and recurring revenue.
📊 Our read: WATCHLIST. Full analysis →
https://stockduty.xyz/s/NTRA0622
Why it matters
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.